Joshuaine Grant Joins Applied BioMath, LLC as Senior Principal Scientist

CONCORD, Mass., Sept. 30, 2019 /PRNewswire/ — Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, is proud to welcome Joshuaine Grant as Senior Principal Scientist.

Joshuaine Grant is a biochemist and mathematical modeler with 22 years of experience in the pharmaceutical industry. Prior to joining Applied BioMath, Joshuaine worked as a biochemist at Protein Sciences Corporation, Bayer Pharmaceuticals and Boehringer Ingelheim Pharmaceuticals. She performed protein purification, biophysical characterization, and assay development to support high throughput screening and structural research for a variety of protein classes including viral proteins, kinases, ubituinases and proteases.

In 2008, Joshuaine joined the Systems Biology group at Boehringer Ingelheim Pharmaceuticals where she used QSP and PK/PD modeling to support target identification, lead selection, and preclinical study design in early discovery research, for both large and small molecules. For programs entering development, she predicted the therapeutic dose in humans and supported dosing strategies in Phase I. In 2017, she joined the department of Translational Medicine and Clinical Pharmacology where she provided pharmacometrics and QSP modeling support for clinical development programs. During her time at Boehringer Ingelheim she supported programs in immunology, oncology, and cardiometabolic diseases.

“We are thrilled to have Joshuaine join the team!” said John Burke, PhD, Co-Founder, President & CEO, Applied BioMath. “Joshuaine’s combination of mathematical modeling and biochemistry experience are a unique find in modelers.  Her deep experience in early and late stage projects, as well as in project management is also a very strong asset. This experience gives her a much deeper understanding of how best to apply computational and cross-disciplinary approaches to drug R&D.”

About Applied BioMath

Founded in 2013, Applied BioMath uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development. Their Model-Aided Drug Invention (MADI) approach employs proprietary algorithms and software to support groups worldwide in decision-making from early research through clinical trials. The Applied BioMath team leverages their decades of expertise in biology, mathematical modeling and analysis, high-performance computing, and industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, patients, and the best path forward into and in the clinic. For more information about Applied BioMath and its services, visit www.appliedbiomath.com.

Applied BioMath and the Applied BioMath logo are registered trademarks of Applied BioMath, LLC.

Press contact:

Kristen Zannella

kristen.zannella@appliedbiomath.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/joshuaine-grant-joins-applied-biomath-llc-as-senior-principal-scientist-300927905.html

SOURCE Applied BioMath, LLC

Staff

Recent Posts

Rapid Dose Announces Proposed Issuance of Shares as Payment of Director Fees

Burlington, Ontario--(Newsfile Corp. - December 24, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or…

7 minutes ago

Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan

DUBLIN, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology…

7 minutes ago

Carmell Announces PIPE Investment From Existing and New Investors To Support Commercial Build-out

PITTSBURGH, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused…

7 minutes ago

AI/ML Innovations Closes Acquisition of Quantum Sciences Ltd.

Strategic Expansion into Cardio AI-Driven Healthcare SolutionsCollaboration to Enhance Patient-Centered Digital Healthcare TechnologiesWelcomes Key Industry…

3 hours ago

cbdMD Announces Company’s CEO Joins the Board of Directors

Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…

17 hours ago

Interactive Strength Inc. (Nasdaq: TRNR) Issues Year-End Update, Looks Ahead to 2025

AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…

18 hours ago